GLP-1内卷升级!信达“玛仕度肽注射液”& 诺和诺德 “CagriSema注射液”新临床获批!

新药社
Jan 19

今日,国家药品监督管理局药品审评中心(CDE)显示,两款重磅的GLP-1类药再获新适应症临床,GLP-1赛道内卷再次升级:信达生物—玛仕度肽注射液:高血压合并超重/肥胖人群的血压控制。诺和诺德—CagriSema注射液:用于低热量饮食和增加体力活动的基础上,8至18岁以下儿童及青少年的长期体重管理。(图片来源:CDE官网)关注新药社,每日为你介绍全球新药信息玛仕度肽注射液:中国原创双靶点药物,拓展...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10